Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Adecoagro SA (AGRO) Price & Performance

Abbott LaboratoriesTrade
Adecoagro SATrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Adecoagro SA — how do they compare? Abbott Laboratories trades at $111.08 (market cap $187.95B), while Adecoagro SA trades at $9.32 (market cap $1.36B). The key difference: Abbott Laboratories is far larger — about 138.2× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.15%). Which is the better fit depends on your goals.

ABTAGRO
Market Cap
$187.95B$1.36B
Sector
HealthTechnology
52-Week High
$136.62$15.25
52-Week Low
$82.57$7.13
Enterprise Value
$214.96B$3.39B
Dividend Yield
2.32%3.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Adecoagro SA

AGRO trades at $9.34, down 3.31% today, with a bearish technical signal from moving averages. The company reported mixed earnings, beating in Q3 2025 but missing in the last three quarters. Recent news highlights record adjusted EBITDA in Q2 2026 and an acquisition to expand operations. Valuation ratios like P/S of 0.71 and P/B of 0.77 suggest potential undervaluation, but low net income margins and negative recent EPS pose challenges.

The outlook is cautious; analyst consensus is mixed with 37.5% buy ratings. Upside potential exists from operational expansions and cost management, but risks include earnings volatility, high leverage from acquisitions, and commodity price exposure. Investors should weigh the low valuation against inconsistent profitability and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Adecoagro SA

Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.

Read more on AGRO